Elecsys^® Troponin T-high sensitive

In the case of suspected AMI, prompt treatment is essential. Every 30 minutes of delay between symptoms and treatment increases the 1-year mortality rate by 7.5%.⁷

Troponin is the preferred biomarker in defining AMI according to the European Society of Cardiology (ESC) guidelines.8 In addition, it is the gold standard to distinguish between AMI and non-AMI patients.^8,9

Elecsys® Troponin T-high sensitive (TnT-hs) can reduce the time needed to rule-in or rule-out NSTEMI to as little as just 1 hour.^4-6

Safely reduce time to diagnosis

• Triage over 75% of patients within 1 hour as validated by three multicenter studies with over 3,000 patients^1-6
• Safely rule-out AMI and confidently discharge patients based on a high negative predictive value (99.1% - 100%) and low 30 day mortality rate (0.0% - 0.2%)^1-3

Lower the need for cardiac stress testing 

• Significantly reduce the need for cardiac stress testing by exercise electrocardiogram (ECG)^{5, 10}

Shorten stays in the emergency department (ED)

• Facilitate early discharge or transfer from the ED by reducing time spent in ED by 2.1 hours (33%) vs standard practice^{4-6, 10, 11}